Skip to main content
Maccura Biotechnology Co.,Ltd logo

Maccura Biotechnology Co.,Ltd — Investor Relations & Filings

Ticker · 300463 ISIN · CNE1000020H3 LEI · 300300D1OBFM39B0QG96 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,713 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300463

About Maccura Biotechnology Co.,Ltd

https://www.maccura.com

Maccura Biotechnology Co.,Ltd. specializes in the research, development, manufacturing, and distribution of in vitro diagnostic (IVD) products. The company provides comprehensive laboratory solutions encompassing clinical chemistry, immunoassay, hematology, coagulation, urinalysis, and molecular diagnostics. Its product portfolio includes automated analyzers, high-throughput chemiluminescence systems, and a wide range of compatible reagents designed for clinical laboratories and healthcare institutions. Maccura focuses on delivering integrated diagnostic systems that enhance laboratory efficiency and diagnostic accuracy. By maintaining a robust R&D pipeline and a global service network, the company supports diverse medical testing requirements, ranging from routine screenings to specialized clinical assays. Its commitment to technological innovation and quality standardization positions it as a key provider of total laboratory automation and point-of-care testing solutions.

Recent filings

Filing Released Lang Actions
上海市锦天城律师事务所关于迈克生物股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter from a law firm regarding the convening, procedure, and voting results of the company’s 2025 annual shareholders’ meeting. It does not present an AGM presentation (AGM-R), proxy materials (PSI), or the actual annual report (10-K), nor is it a pure declaration of voting results by the company (DVA). Instead, it serves as a compliance/legal certification letter. Such officer certifications and legal opinion letters fall under the General Regulatory Filings category (RNS).
2026-05-20 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 96% confidence The document is an official notice of the 2025 annual general meeting resolutions of 迈克生物股份有限公司, detailing attendance, each proposal voted on, vote counts and percentages, and legal opinions – i.e., the declaration of voting results from a shareholder meeting. This fits the ‘Declaration of Voting Results & Voting Rights Announcements’ category (Code: DVA).
2026-05-20 Chinese
关于公司新产品取得产品注册证书的公告
Regulatory Filings Classification · 70% confidence The document is a corporate announcement about the company’s new product obtaining a medical device registration certificate. It contains no financial statements, no shareholder meeting details, no dividend or share transaction information, nor is it a formal financial report. It is a general disclosure of regulatory approval, fitting the generic “Regulatory Filings” category (RNS) as a fallback for miscellaneous compliance announcements.
2026-05-14 Chinese
关于召开2025年年度股东会的提示性公告
Proxy Solicitation & Information Statement Classification · 93% confidence The document is a formal notice announcing the convening of the 2025 annual shareholders’ meeting, outlining the meeting date, voting arrangements, agenda items, registration procedures, and including proxy and registration forms as attachments. It is a solicitation of proxies and information statement for shareholders’ voting rather than the full annual report, election results, or minutes. This fits the “Proxy Solicitation & Information Statement (PSI)” category.
2026-05-14 Chinese
关于担保进展的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company (迈克生物股份有限公司) regarding the progress of guarantees provided by the company for its dealers to banks. It includes details about the guarantee agreements, the parties involved, financial data of the guaranteed party, and cumulative guarantee amounts. The document is structured as a formal announcement with no comprehensive financial statements or management discussion and analysis. It does not present a full annual or interim report, nor is it a transcript, audit report, or other specialized filing. The document length is 3569 characters, which is relatively short and typical for an announcement. The content focuses on guarantee progress and related contractual details, which fits the profile of a regulatory announcement about financing or guarantees. Given the nature of the content and the absence of full financial reports, this document best fits the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-11-10 Chinese
关于公司新产品取得产品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a new product registration certificate from the National Medical Products Administration. It details the product name, registration certificate number, category, validity period, intended use, and the impact on the company. The document is short (882 characters) and serves as an official announcement rather than a detailed report or financial statement. It does not contain financial data, management discussion, or regulatory certifications. It is not related to financial results, governance changes, or legal proceedings. Therefore, it fits best as a Regulatory Filing (RNS), which is a general category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-11-07 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.